學門類別
最新個案
- Leadership Imperatives in an AI World
- Vodafone Idea Merger - Unpacking IS Integration Strategies
- V21 Landmarks Pvt. Ltd: Scaling Newer Heights in Real Estate Entrepreneurship
- Snapchat’s Dilemma: Growth or Financial Sustainability
- Did I Just Cross the Line and Harass a Colleague?
- Predicting the Future Impacts of AI: McLuhan’s Tetrad Framework
- Porsche Drive (A) and (B): Student Spreadsheet
- Porsche Drive (B): Vehicle Subscription Strategy
- TNT Assignment: Financial Ratio Code Cracker
- Winsol: An Opportunity For Solar Expansion
BGI Genomics: Strategic Corporate Social Responsibility
內容大綱
BGI Genomics (BGI), founded in China in 1999, covered the entire field of genomic sequencing applications. During the COVID-19 pandemic in 2020, BGI’s strategic corporate social responsibility initiative, developing coronavirus nucleic acid test kits, created shared value for BGI and society; brought revenue growth to the company; and won BGI acclamation from the government, media, and public. However, as the market competition in the COVID-19 testing business intensified, Zhao Lijian, chief executive officer of BGI, had to consider the company’s next direction: Should BGI significantly increase investment in the COVID-19 testing business and shoulder greater social responsibility for fighting the pandemic? Or should it shift the focus back to its main business?
學習目標
This case is suitable for courses on corporate ethics and corporate social responsibility at all levels (undergraduate, graduate, and postgraduate). After completing the case and assignment questions, students will be able to<ul><li>grasp the concept of strategic corporate social responsibility;</li><li>understand how to identify and fulfill strategic corporate social responsibility;</li><li>understand the relationship between strategic corporate social responsibility and corporate competitive advantage; and</li><li>develop a long-term mindset.</li></ul>